Literature DB >> 23892229

Maintaining energy homeostasis is an essential component of Wld(S)-mediated axon protection.

Hua Shen1, Krzysztof L Hyrc, Mark P Goldberg.   

Abstract

Wld(S) mutation protects axons from degeneration in diverse experimental models of neurological disorders, suggesting that the mutation might act on a key step shared by different axon degeneration pathways. Here we test the hypothesis that Wld(S) protects axons by preventing energy deficiency commonly encountered in many diseases. We subjected compartmentally cultured, mouse cortical axons to energy deprivation with 6mM azide and zero glucose. In wild-type (WT) culture, the treatment, which reduced axon ATP level ([ATP]axon) by 65%, caused immediate axon depolarization followed by gradual free calcium accumulation and subsequent irreversible axon damage. The calcium accumulation resulted from calcium influx partially via L-type voltage-gated calcium channel (L-VGCC). Blocking L-VGCC with nimodipine reduced calcium accumulation and protected axons. Without altering baseline [ATP]axon, the presence of Wld(S) mutation significantly reduced the axon ATP loss and depolarization, restrained the subsequent calcium accumulation, and protected axons against energy deprivation. Wld(S) neurons possessed higher than normal nicotinamide mononucleotide adenylyltransferase (NMNAT) activity. The intrinsic Wld(S) NMNAT activity was required for the Wld(S)-mediated energy preservation and axon protection during but not prior to energy deprivation. NMNAT catalyzes the reversible reaction that produces nicotinamide adenine dinucleotide (NAD) from nicotinamide mononucleotide (NMN). Interestingly, preventing the production of NAD from NMN with FK866 increased [ATP]axon and protected axons from energy deprivation. These results indicate that the Wld(S) mutation depends on its intrinsic Wld(S) NMNAT activity and the subsequent increase in axon ATP but not NAD to protect axons, implicating a novel role of Wld(S) NMNAT in axon bioenergetics and protection.
© 2013.

Entities:  

Keywords:  ATP; ATP level in axons; ATP levels in cell bodies; AUC; Axon injury; Bioenergetics; Calcium; DFI; DIV; Dibac(4)(3); Dibac(4)(3) fluorescence intensity; Energy deprivation; GA; L-VGCC; L-type voltage-gated calcium channel; MTR; MitoTracker Red CMXRos; NAD; NAM; NAMPT; NMN; NMNAT; PPi; PRPP; ROI; WT; Wld(S); [ATP](axon); [ATP](cell); [Ca(2+)](axon); area under the curve; bis(1,3-dibutylbarbituric acid) trimethine oxonol; days in vitro; free calcium concentration in axon; gallotannin; hours post injury; hpi; nicotinamide; nicotinamide adenine dinucleotide; nicotinamide mononucleotide; nicotinamide mononucleotide adenylyltransferase; nicotinamide phosphoribosyltransferase; phosphoribosylpyrophosphate; pyrophosphate; region of interest; wild-type

Mesh:

Substances:

Year:  2013        PMID: 23892229      PMCID: PMC3787137          DOI: 10.1016/j.nbd.2013.07.007

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  60 in total

1.  Ion transport and membrane potential in CNS myelinated axons. II. Effects of metabolic inhibition.

Authors:  L Leppanen; P K Stys
Journal:  J Neurophysiol       Date:  1997-10       Impact factor: 2.714

2.  Endogenous Nmnat2 is an essential survival factor for maintenance of healthy axons.

Authors:  Jonathan Gilley; Michael P Coleman
Journal:  PLoS Biol       Date:  2010-01-26       Impact factor: 8.029

3.  Characterization of recombinant human nicotinamide mononucleotide adenylyl transferase (NMNAT), a nuclear enzyme essential for NAD synthesis.

Authors:  M Schweiger; K Hennig; F Lerner; M Niere; M Hirsch-Kauffmann; T Specht; C Weise; S L Oei; M Ziegler
Journal:  FEBS Lett       Date:  2001-03-09       Impact factor: 4.124

4.  Ions, energy and axonal injury: towards a molecular neurology of multiple sclerosis.

Authors:  Stephen G Waxman
Journal:  Trends Mol Med       Date:  2006-03-30       Impact factor: 11.951

5.  Creatine pretreatment protects cortical axons from energy depletion in vitro.

Authors:  Hua Shen; Mark P Goldberg
Journal:  Neurobiol Dis       Date:  2012-04-11       Impact factor: 5.996

6.  Hypoxic injury of isolated axons is independent of ionotropic glutamate receptors.

Authors:  Suzanne M Underhill; Mark P Goldberg
Journal:  Neurobiol Dis       Date:  2006-10-27       Impact factor: 5.996

7.  Absence of Wallerian Degeneration does not Hinder Regeneration in Peripheral Nerve.

Authors:  E R Lunn; V H Perry; M C Brown; H Rosen; S Gordon
Journal:  Eur J Neurosci       Date:  1989       Impact factor: 3.386

8.  Inhibiting axon degeneration and synapse loss attenuates apoptosis and disease progression in a mouse model of motoneuron disease.

Authors:  Anna Ferri; Joshua R Sanes; Michael P Coleman; Jeanette M Cunningham; Ann C Kato
Journal:  Curr Biol       Date:  2003-04-15       Impact factor: 10.834

9.  Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival.

Authors:  Hongying Yang; Tianle Yang; Joseph A Baur; Evelyn Perez; Takashi Matsui; Juan J Carmona; Dudley W Lamming; Nadja C Souza-Pinto; Vilhelm A Bohr; Anthony Rosenzweig; Rafael de Cabo; Anthony A Sauve; David A Sinclair
Journal:  Cell       Date:  2007-09-21       Impact factor: 41.582

10.  Delayed synaptic degeneration in the CNS of Wlds mice after cortical lesion.

Authors:  Thomas H Gillingwater; Cali A Ingham; Katherine E Parry; Ann K Wright; Jane E Haley; Thomas M Wishart; Gordon W Arbuthnott; Richard R Ribchester
Journal:  Brain       Date:  2006-06       Impact factor: 13.501

View more
  16 in total

1.  Sodium and potassium currents influence Wallerian degeneration of injured Drosophila axons.

Authors:  Bibhudatta Mishra; Ross Carson; Richard I Hume; Catherine A Collins
Journal:  J Neurosci       Date:  2013-11-27       Impact factor: 6.167

Review 2.  Glucose metabolism in nerve terminals.

Authors:  Ghazaleh Ashrafi; Timothy A Ryan
Journal:  Curr Opin Neurobiol       Date:  2017-06-09       Impact factor: 6.627

Review 3.  Mechanisms of distal axonal degeneration in peripheral neuropathies.

Authors:  Christopher R Cashman; Ahmet Höke
Journal:  Neurosci Lett       Date:  2015-01-21       Impact factor: 3.046

Review 4.  Programming axonal mitochondrial maintenance and bioenergetics in neurodegeneration and regeneration.

Authors:  Xiu-Tang Cheng; Ning Huang; Zu-Hang Sheng
Journal:  Neuron       Date:  2022-04-16       Impact factor: 18.688

5.  Structural and Functional Rescue of Chronic Metabolically Stressed Optic Nerves through Respiration.

Authors:  Mohammad Harun-Or-Rashid; Nate Pappenhagen; Peter G Palmer; Matthew A Smith; Victoria Gevorgyan; Gina N Wilson; Samuel D Crish; Denise M Inman
Journal:  J Neurosci       Date:  2018-05-14       Impact factor: 6.167

Review 6.  Wallerian degeneration: an emerging axon death pathway linking injury and disease.

Authors:  Laura Conforti; Jonathan Gilley; Michael P Coleman
Journal:  Nat Rev Neurosci       Date:  2014-06       Impact factor: 34.870

Review 7.  Multifactorial Pathogenic Processes of Retinal Ganglion Cell Degeneration in Glaucoma towards Multi-Target Strategies for Broader Treatment Effects.

Authors:  Gülgün Tezel
Journal:  Cells       Date:  2021-06-02       Impact factor: 6.600

8.  A rise in NAD precursor nicotinamide mononucleotide (NMN) after injury promotes axon degeneration.

Authors:  M Di Stefano; I Nascimento-Ferreira; G Orsomando; V Mori; J Gilley; R Brown; L Janeckova; M E Vargas; L A Worrell; A Loreto; J Tickle; J Patrick; J R M Webster; M Marangoni; F M Carpi; S Pucciarelli; F Rossi; W Meng; A Sagasti; R R Ribchester; G Magni; M P Coleman; L Conforti
Journal:  Cell Death Differ       Date:  2014-10-17       Impact factor: 15.828

Review 9.  Concepts for regulation of axon integrity by enwrapping glia.

Authors:  Bogdan Beirowski
Journal:  Front Cell Neurosci       Date:  2013-12-19       Impact factor: 5.505

10.  The axon-protective WLD(S) protein partially rescues mitochondrial respiration and glycolysis after axonal injury.

Authors:  Katharina Godzik; Michael P Coleman
Journal:  J Mol Neurosci       Date:  2014-10-29       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.